ASBP
Aspire Biopharma Holdings, Inc.0.1043
-0.0031-2.89%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
14.44MP/E (TTM)
-Basic EPS (TTM)
-0.64Dividend Yield
0%Recent Filings
8-K
New $100M ELOC replaces prior
Aspire Biopharma terminated its prior $100M ELOC with Arena and inked a fresh one on November 11, 2025, securing optional access to another $100M in common stock sales at 96% of VWAP. It issued Transaction Fee Shares covering $40,000 in fees and committed 250,000 Commitment Fee Shares post-registration effectiveness. New facility replaces the old. Caps apply sans shareholder approval.
10-Q
Q3 FY2025 results
Aspire Biopharma notched its first revenue of $1,941 in Q3 FY2025 ended September 30, up from zero a year earlier, yielding $884 gross profit while operating expenses swelled to $1.1M from $215K on higher R&D and marketing. Net loss hit $1.85M, versus $216K prior year, as $1.48M interest expense from convertible notes outpaced $775K derivative gains. Cash sits at $1.95M after $4M ops burn, backed by $13.9M liabilities including $4.7M convertibles; financing propped $5.9M inflows. Reverse recap closed February 2025. Nasdaq delisting risk looms from low market value.
8-K
Reverse split, notes approved
Aspire Biopharma stockholders approved a reverse stock split on November 4, 2025, granting the board discretion for a 1-for-5 to 1-for-40 ratio within one year. They also ratified issuance of over 19.99% of outstanding shares upon conversion of August 19 Convertible Promissory Notes at a 20% floor price discount. Vote tallies: 25M for split, 20M for notes. Compliance secured.
8-K
Nasdaq delisting notice appealed
Aspire Biopharma failed to meet Nasdaq's $50M MVLS and $1 bid price rules despite 180-day cures, triggering a October 15, 2025 delisting notice. Company appealed to the Hearings Panel, paying $20,000 to stay suspension while pitching a compliance plan. Delisting looms. Panel may grant up to 180 more days—but success isn't assured.
8-K
Funds second tranche, swaps auditors
Aspire Biopharma funded its second tranche of $1M on September 22, 2025, under a prior $7.75M note agreement, bringing total proceeds to the full amount. That day, it dismissed auditor Bush—whose prior report flagged going concern doubts but no disagreements—and tapped Turner Stone as replacement. Clean switch. Material weaknesses in controls persist from 2024 10-K.
AEON
AEON Biopharma, Inc.
1.03+0.17
ATHA
Athira Pharma, Inc.
3.88+0.03
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
INSP
Inspire Medical Systems, Inc.
115.51-3.75
JSPR
Jasper Therapeutics, Inc.
1.71+0.07
MTNB
Matinas Biopharma Holdings, Inc
0.74+0.01
NTRB
Nutriband Inc.
4.49-0.35
PULM
Pulmatrix, Inc.
4.10-0.25
SEPSF
ASEP Medical Holdings Inc.
0.01+0.00
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07